6 O
ADVERSE O
REACTIONS O
If O
VIEKIRA O
PAK O
is O
administered O
with O
ribavirin O
( O
RBV O
) O
, O
refer O
to O
the O
prescribing O
information O
for O
ribavirin O
for O
a O
list O
of O
ribavirin-associated O
adverse O
reactions O
. O

The O
following O
adverse O
reaction O
is O
described O
below O
and O
elsewhere O
in O
the O
labeling O
: O
* O
Increased O
Risk O
of O
ALT B-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
EXCERPT O
: O
In O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
, O
the O
most O
commonly O
reported O
adverse O
reactions O
( O
greater O
than O
10 O
% O
of O
subjects O
) O
were O
fatigue O
, O
nausea O
, O
pruritus O
, O
other O
skin O
reactions O
, O
insomnia O
and O
asthenia O
. O

In O
subjects O
receiving O
VIEKIRA O
PAK O
without O
ribavirin O
, O
the O
most O
commonly O
reported O
adverse O
reactions O
( O
greater O
than O
or O
equal O
to O
5 O
% O
of O
subjects O
) O
were O
nausea O
, O
pruritus O
and O
insomnia O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
AbbVie O
Inc O
. O
at O
1-800-633-9110 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
VIEKIRA O
PAK O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
safety O
assessment O
was O
based O
on O
data O
from O
six O
Phase O
3 O
clinical O
trials O
in O
more O
than O
2,000 O
subjects O
who O
received O
VIEKIRA O
PAK O
with O
or O
without O
ribavirin O
for O
12 O
or O
24 O
weeks O
. O

VIEKIRA O
PAK O
with O
Ribavirin O
in O
Placebo-Controlled O
Trials O
The O
safety O
of O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
was O
assessed O
in O
770 O
subjects O
with O
chronic O
HCV B-Not_AE_Candidate
infection I-Not_AE_Candidate
in O
two O
placebo-controlled O
trials O
( O
SAPPHIRE-I O
and O
-II O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
) O
] O
. O

Adverse O
reactions O
that O
occurred O
more O
often O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
compared O
to O
placebo O
were O
fatigue B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
, O
other O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
( O
see O
Table O
3 O
) O
. O

The O
majority O
of O
the O
adverse O
reactions O
were O
mild O
in O
severity O
. O

Two O
percent O
of O
subjects O
experienced O
a O
serious O
adverse O
event O
( O
SAE O
) O
. O

The O
proportion O
of O
subjects O
who O
permanently O
discontinued O
treatment O
due O
to O
adverse O
reactions O
was O
less O
than O
1 O
% O
. O

Table O
3 O
. O

Adverse O
Reactions O
with O
> O
=5 O
% O
Greater O
Frequency O
Reported O
in O
Subjects O
with O
Chronic O
HCV O
GT1 O
Infection O
Treated O
with O
VIEKIRA O
PAK O
in O
Combination O
with O
Ribavirin O
Compared O
to O
Placebo O
for O
12 O
Weeks O
SAPPHIRE-I O
and O
-II O
VIEKIRA O
PAK O
+ O
RBV O
12 O
Weeks O
N O
= O
770 O
% O
Placebo O
12 O
Weeks O
N O
= O
255 O
% O
Fatigue B-OSE_Labeled_AE
34 O
26 O
Nausea B-OSE_Labeled_AE
22 O
15 O
Pruritus B-OSE_Labeled_AE
* O
18 O
7 O
Skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
$ O
16 O
9 O
Insomnia B-OSE_Labeled_AE
14 O
8 O
Asthenia B-OSE_Labeled_AE
14 O
7 O
*Grouped O
term O
' O
pruritus B-OSE_Labeled_AE
' O
included O
the O
preferred O
terms O
pruritus B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
. O

$ O
Grouped O
terms O
: O
rash B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
, O
dermatitis B-OSE_Labeled_AE
contact I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
psoriasis B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
. O

VIEKIRA O
PAK O
with O
and O
without O
Ribavirin O
in O
Regimen-Controlled O
Trials O
VIEKIRA O
PAK O
with O
and O
without O
ribavirin O
was O
assessed O
in O
401 O
and O
509 O
subjects O
with O
chronic B-Not_AE_Candidate
HCV I-Not_AE_Candidate
infection I-Not_AE_Candidate
, O
respectively O
, O
in O
three O
clinical O
trials O
( O
PEARL-II O
, O
PEARL-III O
and O
PEARL-IV O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
) O
] O
. O

Pruritus B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
were O
identified O
as O
adverse O
events O
occurring O
more O
often O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
( O
see O
Table O
4 O
) O
. O

The O
majority O
of O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

The O
proportion O
of O
subjects O
who O
permanently O
discontinued O
treatment O
due O
to O
adverse O
events O
was O
less O
than O
1 O
% O
for O
both O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
and O
VIEKIRA O
PAK O
alone O
. O

Table O
4 O
. O

Adverse O
Events O
with O
> O
=5 O
% O
Greater O
Frequency O
Reported O
in O
Subjects O
with O
Chronic O
HCV O
GT1 O
Infection O
Treated O
with O
VIEKIRA O
PAK O
in O
Combination O
with O
Ribavirin O
Compared O
to O
VIEKIRA O
PAK O
for O
12 O
Weeks O
PEARL-II O
, O
-III O
and O
-IV O
VIEKIRA O
PAK O
+ O
RBV O
12 O
Weeks O
N O
= O
401 O
% O
VIEKIRA O
PAK O
12 O
Weeks O
N O
= O
509 O
% O
Nausea B-OSE_Labeled_AE
16 O
8 O
Pruritus B-OSE_Labeled_AE
* O
13 O
7 O
Insomnia B-OSE_Labeled_AE
12 O
5 O
Asthenia B-OSE_Labeled_AE
9 O
4 O
*Grouped O
term O
' O
pruritus B-OSE_Labeled_AE
' O
included O
the O
preferred O
terms O
pruritus B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
generalized I-OSE_Labeled_AE
. O

VIEKIRA O
PAK O
with O
Ribavirin O
in O
Subjects O
with O
Compensated O
Cirrhosis O
VIEKIRA O
PAK O
with O
ribavirin O
was O
assessed O
in O
380 O
subjects O
with O
compensated B-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
who O
were O
treated O
for O
12 O
( O
n=208 O
) O
or O
24 O
( O
n=172 O
) O
weeks O
duration O
( O
TURQUOISE-II O
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.3 O
) O
] O
. O

The O
type O
and O
severity O
of O
adverse O
events O
in O
subjects O
with O
compensated B-Not_AE_Candidate
cirrhosis I-Not_AE_Candidate
was O
comparable O
to O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
cirrhotic I-Not_AE_Candidate
subjects O
in O
other O
phase O
3 O
trials O
. O

Fatigue B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
dyspnea B-OSE_Labeled_AE
occurred O
at O
least O
5 O
% O
more O
often O
in O
subjects O
treated O
for O
24 O
weeks O
. O

The O
majority O
of O
adverse O
events O
occurred O
during O
the O
first O
12 O
weeks O
of O
dosing O
in O
both O
treatment O
arms O
. O

Most O
of O
the O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

The O
proportion O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
for O
12 O
and O
24 O
weeks O
with O
SAEs O
was O
6 O
% O
and O
5 O
% O
, O
respectively O
and O
2 O
% O
of O
subjects O
permanently O
discontinued O
treatment O
due O
to O
adverse O
events O
in O
each O
treatment O
arm O
. O

Skin O
Reactions O
In O
PEARL-II O
, O
-III O
and O
-IV O
, O
7 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
alone O
and O
10 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
reported O
rash B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

In O
SAPPHIRE-I O
and O
-II O
16 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
and O
9 O
% O
of O
subjects O
receiving O
placebo O
reported O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

In O
TURQUOISE-II O
, O
18 O
% O
and O
24 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
for O
12 O
or O
24 O
weeks O
reported O
skin B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

The O
majority O
of O
events O
were O
graded O
as O
mild O
in O
severity O
. O

There O
were O
no O
serious O
events O
or O
severe B-NonOSE_AE
cutaneous I-NonOSE_AE
reactions I-NonOSE_AE
, O
such O
as O
Stevens B-NonOSE_AE
Johnson I-NonOSE_AE
Syndrome I-NonOSE_AE
( I-NonOSE_AE
SJS I-NonOSE_AE
) O
, O
toxic B-NonOSE_AE
epidermal I-NonOSE_AE
necrolysis I-NonOSE_AE
( I-NonOSE_AE
TEN I-NonOSE_AE
) O
, O
erythema B-NonOSE_AE
multiforme I-NonOSE_AE
( I-NonOSE_AE
EM I-NonOSE_AE
) O
or O
drug B-NonOSE_AE
rash I-NonOSE_AE
with I-NonOSE_AE
eosinophilia I-NonOSE_AE
and I-NonOSE_AE
systemic I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
DRESS I-NonOSE_AE
) O
. O

Laboratory O
Abnormalities O
Serum O
ALT O
Elevations O
Approximately O
1 O
% O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
experienced O
post-baseline O
serum O
ALT B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
greater I-OSE_Labeled_AE
than I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
times I-OSE_Labeled_AE
the I-OSE_Labeled_AE
upper I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
( O
ULN O
) O
after O
starting O
treatment O
. O

The O
incidence O
increased O
to O
25 O
% O
( O
4/16 O
) O
among O
women O
taking O
a O
concomitant O
ethinyl O
estradiol O
containing O
medication O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

The O
incidence O
of O
clinically O
relevant O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
among O
women O
using O
estrogens O
other O
than O
ethinyl O
estradiol O
, O
such O
as O
estradiol O
and O
conjugated O
estrogens O
used O
in O
hormone O
replacement O
therapy O
was O
3 O
% O
( O
2/59 O
) O
. O

ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
typically O
asymptomatic O
, O
generally O
occurred O
during O
the O
first O
4 O
weeks O
of O
treatment O
( O
mean O
time O
20 O
days O
, O
range O
8-57 O
days O
) O
and O
most O
resolved O
with O
ongoing O
therapy O
. O

The O
majority O
of O
these O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
assessed O
as O
drug B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
. O

Elevations B-NonOSE_AE
in O
ALT I-NonOSE_AE
were O
generally O
not O
associated O
with O
bilirubin B-NonOSE_AE
elevations I-NonOSE_AE
. O

Cirrhosis B-NonOSE_AE
was O
not O
a O
risk O
factor O
for O
elevated B-NonOSE_AE
ALT I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Serum O
Bilirubin O
Elevations O
Post-baseline O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
at O
least O
2 O
x O
ULN O
were O
observed O
in O
15 O
% O
of O
subjects O
receiving O
VIEKIRA O
PAK O
with O
ribavirin O
compared O
to O
2 O
% O
in O
those O
receiving O
VIEKIRA O
PAK O
alone O
. O

These O
bilirubin B-OSE_Labeled_AE
increases I-OSE_Labeled_AE
were I-OSE_Labeled_AE
predominately I-OSE_Labeled_AE
indirect I-OSE_Labeled_AE
and O
related O
to O
the O
inhibition O
of O
the O
bilirubin O
transporters O
OATP1B1/1B3 O
by O
paritaprevir B-OSE_Labeled_AE
and I-OSE_Labeled_AE
ribavirin I-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
hemolysis I-OSE_Labeled_AE
. O

Bilirubin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
occurred O
after O
initiation O
of O
treatment O
, O
peaked O
by O
study O
Week O
1 O
, O
and O
generally O
resolved O
with O
ongoing O
therapy O
. O

Bilirubin B-NonOSE_AE
elevations I-NonOSE_AE
were O
not O
associated O
with O
serum O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
. O

Anemia/Decreased O
Hemoglobin O
Across O
all O
Phase O
3 O
studies O
, O
the O
mean O
change O
from O
baseline O
in O
hemoglobin O
levels O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
was O
-2.4 O
g/dL O
and O
the O
mean O
change O
in O
subjects O
treated O
with O
VIEKIRA O
PAK O
alone O
was O
-0.5 O
g/dL O
. O

Decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
levels O
occurred O
early O
in O
treatment O
( O
Week O
1-2 O
) O
with O
further O
reductions O
through O
Week O
3 O
. O

Hemoglobin B-OSE_Labeled_AE
values I-OSE_Labeled_AE
remained I-OSE_Labeled_AE
low I-OSE_Labeled_AE
during O
the O
remainder O
of O
treatment O
and O
returned O
towards O
baseline O
levels O
by O
post-treatment O
Week O
4 O
. O

Less O
than O
1 O
% O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
with O
ribavirin O
had O
hemoglobin B-OSE_Labeled_AE
levels I-OSE_Labeled_AE
decrease I-OSE_Labeled_AE
to O
less O
than O
8.0 O
g/dL O
during O
treatment O
. O

Seven O
percent O
of O
subjects O
treated O
with O
VIEKIRA O
PAK O
in O
combination O
with O
ribavirin O
underwent O
a O
ribavirin O
dose O
reduction O
due O
to O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
; O
three O
subjects O
received O
a O
blood O
transfusion O
and O
five O
required O
erythropoietin O
. O

One O
patient O
discontinued O
therapy O
due O
to O
anemia B-OSE_Labeled_AE
. O

No O
subjects O
treated O
with O
VIEKIRA O
PAK O
alone O
had O
a O
hemoglobin B-NonOSE_AE
level I-NonOSE_AE
less I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
g I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
. O

VIEKIRA O
PAK O
in O
HCV/HIV-1 O
Co-infected O
Subjects O
VIEKIRA O
PAK O
with O
ribavirin O
was O
assessed O
in O
63 O
subjects O
with O
HCV B-Not_AE_Candidate
/ I-Not_AE_Candidate
HIV I-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
co I-Not_AE_Candidate
- I-Not_AE_Candidate
infection I-Not_AE_Candidate
who O
were O
on O
stable O
antiretroviral O
therapy O
. O

The O
most O
common O
adverse O
events O
occurring O
in O
at O
least O
10 O
% O
of O
subjects O
were O
fatigue B-OSE_Labeled_AE
( O
48 O
% O
) O
, O
insomnia B-OSE_Labeled_AE
( O
19 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
17 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
16 O
% O
) O
, O
pruritus B-OSE_Labeled_AE
( O
13 O
% O
) O
, O
cough B-OSE_Labeled_AE
( O
11 O
% O
) O
, O
irritability B-OSE_Labeled_AE
( O
10 O
% O
) O
, O
and O
ocular B-OSE_Labeled_AE
icterus I-OSE_Labeled_AE
( O
10 O
% O
) O
. O

Elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
greater O
than O
2 O
x O
ULN O
( O
mostly O
indirect O
) O
occurred O
in O
34 O
( O
54 O
% O
) O
subjects O
. O

Fifteen O
of O
these O
subjects O
were O
also O
receiving O
atazanavir O
at O
the O
time O
of O
bilirubin B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
and O
nine O
also O
had O
adverse O
events O
of O
ocular B-OSE_Labeled_AE
icterus I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
or O
hyperbilirubinemia B-OSE_Labeled_AE
. O

None O
of O
the O
subjects O
with O
hyperbilirubinemia B-NonOSE_AE
had O
concomitant O
elevations B-NonOSE_AE
of I-NonOSE_AE
aminotransferases I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
, O
Adverse O
Reactions O
( O
6.1 O
) O
and O
Clinical O
Studies O
( O
14.6 O
) O
] O
. O

No O
subject O
experienced O
a O
grade O
3 O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
. O

Seven O
subjects O
( O
11 O
% O
) O
had O
at O
least O
one O
post-baseline O
hemoglobin B-OSE_Labeled_AE
value I-OSE_Labeled_AE
of I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
, O
and O
six O
of O
these O
subjects O
had O
a O
ribavirin O
dose O
modification O
; O
no O
subject O
in O
this O
small O
cohort O
required O
a O
blood O
transfusion O
or O
erythropoietin O
. O

Median O
declines B-OSE_Labeled_AE
in I-OSE_Labeled_AE
CD I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
of O
47 O
cells/mm O
3 O
and O
62 O
cells/mm O
3 O
were O
observed O
at O
the O
end O
of O
12 O
and O
24 O
weeks O
of O
treatment O
, O
respectively O
, O
and O
most O
returned O
to O
baseline O
levels O
post-treatment O
. O

Two O
subjects O
had O
CD B-OSE_Labeled_AE
4 I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
T I-OSE_Labeled_AE
- I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
counts I-OSE_Labeled_AE
decrease I-OSE_Labeled_AE
to O
less O
than O
200 O
cells/mm O
3 O
during O
treatment O
without O
a O
decrease B-NonOSE_AE
in I-NonOSE_AE
CD I-NonOSE_AE
4 I-NonOSE_AE
% I-NonOSE_AE
. O

No O
subject O
experienced O
an O
AIDS B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
opportunistic I-NonOSE_AE
infection I-NonOSE_AE
. O

VIEKIRA O
PAK O
in O
Selected O
Liver O
Transplant O
Recipients O
VIEKIRA O
PAK O
with O
ribavirin O
was O
assessed O
in O
34 O
post B-Not_AE_Candidate
- I-Not_AE_Candidate
liver I-Not_AE_Candidate
transplant I-Not_AE_Candidate
subjects O
with O
recurrent B-Not_AE_Candidate
HCV O
infection I-Not_AE_Candidate
. O

Adverse O
events O
occurring O
in O
more O
than O
20 O
% O
of O
subjects O
included O
fatigue B-OSE_Labeled_AE
50 O
% O
, O
headache B-OSE_Labeled_AE
44 O
% O
, O
cough B-OSE_Labeled_AE
32 O
% O
, O
diarrhea B-OSE_Labeled_AE
26 O
% O
, O
insomnia B-OSE_Labeled_AE
26 O
% O
, O
asthenia B-OSE_Labeled_AE
24 O
% O
, O
nausea B-OSE_Labeled_AE
24 O
% O
, O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
21 O
% O
and O
rash B-OSE_Labeled_AE
21 O
% O
. O

Ten O
subjects O
( O
29 O
% O
) O
had O
at O
least O
one O
post-baseline O
hemoglobin B-OSE_Labeled_AE
value I-OSE_Labeled_AE
of I-OSE_Labeled_AE
less I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
. O

Ten O
subjects O
underwent O
a O
ribavirin O
dose O
modification O
due O
to O
decrease O
in O
hemoglobin O
and O
3 O
% O
( O
1/34 O
) O
had O
an O
interruption O
of O
ribavirin O
. O

Five O
subjects O
received O
erythropoietin O
, O
all O
of O
whom O
initiated O
ribavirin O
at O
the O
starting O
dose O
of O
1000 O
to O
1200 O
mg O
daily O
. O

No O
subject O
received O
a O
blood O
transfusion O
[ O
see O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

6.2 O
Post-Marketing O
Adverse O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
angioedema B-OSE_Labeled_AE
) O
have O
been O
observed O
. O

